TRAIL antibody

Catalog No. ABIN187524

This anti-TRAIL antibody is a Mouse Monoclonal antibody detecting TRAIL in WB, FACS, IP, EIA and IHC (fro). Suitable for Human.

Quick Overview for TRAIL antibody (ABIN187524)

Target: TRAIL (TNFSF10) (Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TRAIL antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunoprecipitation (IP), Enzyme Immunoassay (EIA), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: IIIF6

Product Details anti-TRAIL Antibody

Specificity: Recognizes human TRAIL Species Reactivity: Human.

Immunogen: Recombinant human soluble TRAIL (Apo-2L)

Isotype: IgG2b

Application Details

Application Notes: Western blotting Flow Cytometry Immunohistochemistry: Frozen sections Immunoprecipitation ELISA The optimal dilution for a specific application should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: 100 µl of purified antibody in PBS containing 0.02% NaN3. Concentration 1 mg/ml IgG.

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Target Details for TRAIL

Target: TRAIL (TNFSF10) (Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))

Alternative Name: CD253 / TRAIL

Background: Tumor necrosis factor (TNF-)-related apoptosis-inducing ligand (TRAIL, APO-2L) is thought to regulate cell death events in the immune system through TRAIL-R1 (DR4) and TRAIL-R2 (DR5), members of the TNF receptor superfamily. Like the death receptors, including Fas and TNF-R, TRAIL-R1 and TRAIL-R2 have death domains in their cytoplasmic tails that recruit proteins to initiate a cell death signaling cascade. TRAIL (APO-2L) is a 34 kDa type II transmembrane protein. TRAIL forms trimers and is a member of the TNF ligand family. Interaction between TRAIL and TRAIL-R1 and/or TRAIL-R2 rapidly induces apoptosis of TRAIL-sensitive cells. TRAIL can be injected into mice without toxic side effects. Many tumor cells are killed by TRAIL and TRAIL is currently being considered as on of the most promising potential new cancer therapeutics.

Pathways: Apoptosis, Positive Regulation of Endopeptidase Activity